| scholarly article | Q13442814 |
| P50 | author | Til Stürmer | Q88268207 |
| Jennifer L. Lund | Q89058482 | ||
| Hanna K Sanoff | Q89113920 | ||
| P2860 | cites work | Insights into different results from different causal contrasts in the presence of effect-measure modification. | Q35056824 |
| Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy | Q35076584 | ||
| Controlling Time-Dependent Confounding by Health Status and Frailty: Restriction Versus Statistical Adjustment | Q35775682 | ||
| Cancer Survivors: A Booming Population | Q36175334 | ||
| Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients | Q36874822 | ||
| Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database | Q36977050 | ||
| Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. | Q37412279 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients | Q43763447 | ||
| Common problems related to the use of number needed to treat | Q44122257 | ||
| Marginal Structural Models as a Tool for Standardization | Q44241314 | ||
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
| Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study | Q45260921 | ||
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Q57758061 | ||
| Survival after postoperative combination treatment of rectal cancer | Q69647904 | ||
| T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy | Q73164021 | ||
| Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white | Q74802828 | ||
| Participation in cancer clinical trials: race-, sex-, and age-based disparities | Q80179103 | ||
| Postoperative radiotherapy for stage IIIA rectal cancer: is it justified? | Q81707102 | ||
| Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84424073 | ||
| Postoperative adjuvant chemotherapy in rectal cancer operated for cure | Q24201072 | ||
| Identifying specific chemotherapeutic agents in Medicare data: a validation study | Q30413422 | ||
| Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years | Q30418160 | ||
| Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. | Q30422095 | ||
| Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer | Q30422446 | ||
| Development of a comorbidity index using physician claims data | Q30623996 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Utility of the SEER-Medicare data to identify chemotherapy use. | Q30714828 | ||
| Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007 | Q30744596 | ||
| Using claims data to predict dependency in activities of daily living as a proxy for frailty | Q30863566 | ||
| Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data | Q30884451 | ||
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials | Q31014850 | ||
| Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial | Q33415864 | ||
| Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial | Q33417569 | ||
| Nonexperimental Comparative Effectiveness Research Using Linked Healthcare Databases | Q33576469 | ||
| Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. | Q33839100 | ||
| Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results | Q34001872 | ||
| Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. | Q34546881 | ||
| Preoperative versus postoperative chemoradiotherapy for rectal cancer | Q34552041 | ||
| Chemotherapy with preoperative radiotherapy in rectal cancer | Q34570877 | ||
| Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. | Q34579124 | ||
| Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial | Q34607843 | ||
| Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34656367 | ||
| Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study | Q34659103 | ||
| Mesorectal excision for rectal cancer | Q34726877 | ||
| Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations | Q34789588 | ||
| P433 | issue | 3 | |
| P921 | main subject | chemoradiotherapy | Q5090613 |
| P304 | page(s) | 176-186 | |
| P577 | publication date | 2016-02-23 | |
| P1433 | published in | Journal of Geriatric Oncology | Q15817005 |
| P1476 | title | Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy | |
| P478 | volume | 7 |
| Q91792040 | Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients |
| Q31172121 | Feasibility of Representing Data from Published Nursing Research Using the OMOP Common Data Model |
| Q54959817 | Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. |
Search more.